VTGN VistaGen Therapeutics Inc.

-0.03  -2%
Previous Close 1.46
Open 1.5
Price To Book 11
Market Cap 44411817
Shares 31,057,215
Volume 99,759
Short Ratio
Av. Daily Volume 144,234

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 2 top-line data due mid-2019.
Adjunctive Treatment Major Depressive Disorder
Phase 2 data due 1H 2019.
Monotherapy Treatment Major Depressive Disorder
Phase 2 trial to be initiated 1H 2019.
Neuropathic pain
Phase 3 trial in preparation phase.
PH94B nasal spray
Social Anxiety Disorder (SAD)

Latest News

  1. VistaGen Therapeutics Receives AV-101 Japanese Patent for Treatment of Depression and Hyperalgesia
  2. FDA Panel Nod for J&J's Esketamine Is Good News for Allergan, Vistagen
  3. VistaGen Therapeutics Receives Notice of Allowance for U.S. Patent for Treatment of Depression with PH10
  4. The Daily Biotech Pulse: Exelixis Q4 Results, FDA Panel Greenlights J&J's Depression Drug, MacroGenics Prices Offering
  5. VistaGen Therapeutics Reports Fiscal 2019 Third Quarter Financial Results
  6. VistaGen Therapeutics to Present at the 21st Annual BIO CEO & Investor Conference on February 11, 2019
  7. AV-101 Stimulates the Formation of New Brain Cells in Nonclinical Studies
  8. VistaGen Therapeutics Appoints Pharmaceutical Industry Veteran, Ann Cunningham, to its Board of Directors
  9. VistaGen Therapeutics to Present at 11th Annual Biotech Showcase
  10. Do Institutions Own VistaGen Therapeutics, Inc. (NASDAQ:VTGN) Shares?
  11. VistaGen Therapeutics Receives Hong Kong Patent for Methods of Production for AV-101
  12. Consolidated Research: 2018 Summary Expectations for Tapestry, Mallinckrodt public limited company, Moxian, Applied Genetic Technologies, VistaGen Therapeutics, and Oasis Midstream Partners LP — Fundamental Analysis, Key Performance Indications
  13. VistaGen Therapeutics Receives Notices of Allowance in Australia and Japan for AV-101 Patents Covering Treatment of Depression
  14. Health Care Digest: A small biotech goes head first, Gilead's lower tax rate and more
  15. Tech and biotech on collision course, squeezed by the Peninsula's limited space
  16. VistaGen Up on Fast Track Designation to Pain Candidate